Highlights
The Centers for Medicare & Medicaid Services (CMS) on April 27, 2021, released the Fiscal Year (FY) 2022 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Care Hospital (LTCH) Prospective Payment System (PPS) Proposed Rule, which will affect discharges occurring on or after Oct. 1, 2021.
The Proposed Rule would update the payment policies and annual payment rates for the inpatient payment system, update various quality programs and evaluate New Technology Add-On Payment (NTAP) applications, among other changes.
Comments on the Proposed Rule are due by June 28, 2021, and a final rule is expected by Aug. 1, 2021.
The Centers for Medicare & Medicaid Services (CMS) on April 27, 2021, released the Fiscal Year (FY) 2022 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Care Hospital (LTCH) Prospective Payment System (PPS) Proposed Rule, which will affect discharges occurring on or after Oct. 1, 2021. A CMS fact sheet is ava
Global Immunocell Therapy Market Size, Share, Value, and Competitive Landscape 2020
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Global Immunocell Therapy Market Size, Share, Value, and Competitive Landscape 2020
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses.
The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX and gemcitabine-based therapies, which are considered to be gold standard for pancreatic cancer. In patients exhibiting genetic mutations, targeted therapies such as Vitrakvi (larotrectinib), Rozlytrek (entrectinib), Poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib), and Keytruda (pembrolizumab) are currently included in treatment guid